← All trials
NCT04754802
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 24, 2021
- Primary completion
- May 31, 2022
- Completion date
- Aug 31, 2022
- First posted
- Feb 15, 2021
- Last posted
- Dec 2, 2021
- Enrollment
- 208
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- VistaGen Therapeutics, Inc.Lead sponsor
- The Medical Research Network, LLCOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.